A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
05 Jul 2021
05 Jul 2021
Historique:
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
epublish
Résumé
Drug development for specific antiviral agents against coronavirus disease 2019 (COVID-19) is still an unmet medical need as the pandemic continues to spread globally. Although huge efforts for drug repurposing and compound screens have put forth, only few compounds remain in late stage clinical trials. New approaches and assays are needed to accelerate COVID-19 drug discovery and development. Here we report a time-resolved fluorescence resonance energy transfer-based assay that detects the severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) nucleocapsid protein (NP) produced in infected cells. It uses two specific anti-NP monoclonal antibodies (MAbs) conjugated to donor and acceptor fluorophores that produces a robust ratiometric signal for high throughput screening of large compound collections. Using this assay, we measured a half maximal inhibitory concentration (IC
Identifiants
pubmed: 34268508
doi: 10.1101/2021.07.03.450938
pmc: PMC8282096
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Références
ACS Nano. 2020 Sep 22;14(9):12234-12247
pubmed: 32845122
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Int J Mol Sci. 2020 Oct 27;21(21):
pubmed: 33121109
Protein Sci. 2020 Sep;29(9):1890-1901
pubmed: 32654247
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
JAMA. 2021 Feb 9;325(6):529-531
pubmed: 33404586
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
ACS Pharmacol Transl Sci. 2020 Nov 17;3(6):1352-1360
pubmed: 33330843
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
Lancet Microbe. 2021 Jul;2(7):e283-e284
pubmed: 33846703
ACS Pharmacol Transl Sci. 2020 Oct 09;3(6):1233-1241
pubmed: 33330840
Front Pharmacol. 2021 Jan 25;11:592737
pubmed: 33708112
Curr Pharm Biotechnol. 2016;17(14):1222-1230
pubmed: 27604358
Protein Cell. 2021 Apr 17;:
pubmed: 33864621
Curr Chem Genomics. 2009 May 28;3:22-32
pubmed: 20161833
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Viruses. 2019 Oct 24;11(11):
pubmed: 31652964
Nucleic Acids Res. 2003 Jul 1;31(13):3784-8
pubmed: 12824418
Adv Virus Res. 1961;8:245-85
pubmed: 14038270
Curr Biol. 2020 Apr 6;30(7):1346-1351.e2
pubmed: 32197085
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Trials. 2020 May 24;21(1):422
pubmed: 32448345
J Med Virol. 2021 Apr;93(4):2132-2140
pubmed: 33090512
ACS Pharmacol Transl Sci. 2020 Sep 04;3(5):1008-1016
pubmed: 33062953
J Biosci. 2020;45:
pubmed: 32515358
J Pharmacol Exp Ther. 2020 Oct;375(1):127-138
pubmed: 32723801
ACS Pharmacol Transl Sci. 2020 Oct 19;3(6):1165-1175
pubmed: 33330839
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33766889
JAMA. 2021 Apr 6;325(13):1318-1320
pubmed: 33635317
Assay Drug Dev Technol. 2015 Jan-Feb;13(1):44-54
pubmed: 25710545
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Biochem Biophys Res Commun. 2020 Jun 30;527(3):618-623
pubmed: 32416961
Antiviral Res. 2021 Jun;190:105078
pubmed: 33894278
Euro Surveill. 2020 Oct;25(39):
pubmed: 33006300